Sativa Investments PLC (NEX:SATI), the UK’s first medicinal cannabis investment vehicle, announced today that it is seeking shareholder approval to broaden its investment policy beyond Canada and has today notified shareholders of a General Meeting to be held on 22 June 2018, in order to seek their approval. The Company is also seeking shareholder approval relating to authority to allot shares and also relating to the disapplication of pre-emption rights. A copy of the Circular, which was posted today, is available on the Company’s website www.sativainvestments.com
Since listing on the NEX Exchange Growth Market on Thursday 29th March 2018, Sativa has pursued numerous potential investments and has already announced two investments, these being in Veritas Pharma Inc. and Rapid Dose Therapeutics Inc. on 21 May and 23 May respectively.
Geremy Thomas, founder and Chief Executive Officer of Sativa Investments PLC, said: “Even since Sativa’s IPO in March this year, the global interest in medicinal cannabis has grown considerably. The increased political attention to generic access to what are established and legal therapies in many jurisdictions means that the opportunity to build shareholder value goes far beyond medicinal cannabis ventures in Canada alone.
“The UK is seeing an increasing debate over access to medicinal cannabis and legislatory change here is a realistic possibility, with the Legalisation of Cannabis (Medicinal Purposes) Bill 2017-19 expected to have its second reading debate in Parliament on Friday 6 July 2018, a scenario which is likely to be mirrored across Europe. Sativa is well placed to participate in meeting any future European or wider global demand whilst continuing to invest in the well-established Canadian market.”
